GLIOBLASTOMA

This early-phase study tests whether a personalized vaccine made from a patient's own tumor mutations can safely boost the immune system to fight glioblastoma, an aggressive brain cancer. About 56 newly diagnosed patients receive the vaccine along with radiation and sometimes the…

This early-phase study tested a personalized DNA vaccine in 9 people with a fast-growing type of brain cancer called glioblastoma. The vaccine was custom-made for each patient based on their tumor's unique genetic mutations. The main goals were to see if the vaccine was safe, pos…

This study tests a vaccine called SurVaxM, given with standard chemotherapy, for people with a newly diagnosed aggressive brain cancer (glioblastoma). The vaccine is designed to train the immune system to attack cancer cells. The main goal is to see if adding the vaccine helps ke…

This early-phase study tests whether adding a personalized vaccine (made from each patient's tumor mutations) to standard care plus Tumor Treating Fields is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. Thirteen adults with stable disease after in…

This study tests a combination of a drug (niraparib) and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if this approach can stop the tumor from gr…

This program provides gallium maltolate (GaM) to adults with glioblastoma that has come back or not responded to treatment, and who have run out of standard options. The goal is to offer a possible way to control the disease when nothing else is available. Participants must be 18…

This early-phase study tests the safety of adding the drug ibrutinib to standard radiation and chemotherapy for people with a fast-growing brain cancer called glioblastoma. About 36 participants will receive different doses to find the safest amount. The goal is to control the di…

This study tests whether adding a special radiation tile (GammaTile) during brain surgery for newly diagnosed glioblastoma is safe and practical when followed by standard chemotherapy and radiation. About 61 adults will receive the tile at the time of tumor removal, then continue…

This study tests a new treatment for people with recurrent glioblastoma, an aggressive brain cancer. The approach combines immune cells (dendritic cells) with two immunotherapy drugs (ipilimumab and nivolumab) given directly into the tumor during surgery, followed by more doses i…

This study tests whether taking two targeted pills (dabrafenib and trametinib) after radiation therapy can help children and young adults up to age 25 with a specific type of aggressive brain cancer (BRAF V600-mutant high-grade glioma). The drugs block proteins that fuel tumor gr…

This study tests a drug called tofacitinib in 17 people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if it can slow tumor growth and extend survival. Participants take the drug twice daily, and researchers monitor progression and side effects.

This early-phase trial tests whether adding mycophenolate mofetil (a drug usually used to prevent organ rejection) to standard chemotherapy and radiation can help treat glioblastoma, an aggressive brain cancer. The study involves 60 newly diagnosed or recurrent glioblastoma patie…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors more effectively. It involves 57 patients with recurrent glioblastoma, a fast-growing brain cancer. The goal is to find a safe dose and se…

This early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH1/2-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnose…

This study tests whether removing a larger area of brain tissue around a glioblastoma tumor (called supramarginal resection) can help patients live longer. It includes 90 adults with suspected glioblastoma who are healthy enough for surgery. The approach aims to remove more hidde…

This early-phase study tests whether specially engineered immune cells (CART-EGFR-IL13Ra2) are safe and feasible for people with a recurrent, aggressive brain cancer called glioblastoma. About 67 adults whose tumors have returned after standard treatment will receive their own mo…

This phase 3 trial tests whether giving a dose of radiation directly to the tumor cavity during surgery can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without the cancer growing. About 314 adults aged 18 to 80 are taking part. The k…

This study tests a new treatment for glioblastoma, an aggressive brain cancer. Patients take two drugs (paxalisib and metformin) and follow a high-fat, low-carbohydrate (ketogenic) diet. The goal is to see if this combination is safe and can slow tumor growth. The trial includes …

This study tested whether a low-carb, high-fat diet (ketogenic diet) could help control glioblastoma, an aggressive brain cancer. Sixteen adults with the disease followed the diet alongside standard care. Researchers used MRI scans to see if the diet reduced tumor size or slowed …

This early-stage study tests an oral drug called gallium maltolate in 26 adults whose glioblastoma has returned or not responded to standard treatments. The main goal is to find a safe dose and see if it can slow tumor growth. Participants take the drug by mouth and are monitored…

This study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…

This early-stage study tests a radioactive drug called [177Lu]Lu-DOTA-TATE in people with glioblastoma, an aggressive brain cancer. For newly diagnosed patients, it is given alongside standard radiation and chemotherapy. For those with recurrent cancer, it is given alone. The mai…

This early-stage trial tests whether adding two experimental DNA vaccines (INO-5401 and INO-9012) and an immunotherapy drug (cemiplimab) to standard radiation and chemotherapy can help people with newly-diagnosed glioblastoma, an aggressive brain cancer. The study enrolls 52 part…

This early-phase trial studies whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can help the immune system fight recurrent glioblastoma, an aggressive brain cancer. About 63 adults whose cancer returned after standard treatment will receive the dru…

This early-phase trial tests whether specially engineered immune cells (T cells) can safely target and kill recurrent malignant glioma, an aggressive brain cancer. About 29 patients will receive these cells to find the best dose and check for side effects. The goal is to control …

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests whether adding the drug nivolumab to radiation therapy and another drug (bevacizumab) can help people with a returning type of brain cancer called glioblastoma. The trial includes 39 adults whose cancer has come back after standard treatment. The goal is to see i…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain cancer called glioblastoma (grade 4 glioma). It includes both newly diagnosed and recurrent patients. The study first checks how much drug reaches …

This early-phase study tests whether adding high-dose vitamin C and an iron-based drug (ferumoxytol) to standard radiation and chemotherapy can help adults with a newly diagnosed aggressive brain tumor called glioblastoma. The main goal is to find a safe dose of the iron drug. Se…

This study tests a combination of two drugs, L19TNF and lomustine, in about 90 adults whose glioblastoma has come back or worsened. The goal is to find the best dose that is safe and may help people live longer. Participants will be monitored for side effects and survival over 12…

This study tests whether adding a second chemotherapy drug (lomustine) to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma, a fast-growing brain cancer. The trial includes 265 adults whose tumors have a genetic marker (MGMT me…

This program gives certain glioblastoma patients at Roswell Park access to SurVaxM, a treatment that may help slow tumor growth and extend survival. It is for patients who have no other treatment options or who have already benefited from SurVaxM in a prior study. The goal is to …

This study tests a new combination of three treatments for people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal is to see if adding the immunotherapy drug pembrolizumab to standard chemotherapy and electric field therapy (Optune) can help patients live l…

This study tests whether adding the drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 18 participants will receive the combination to find the best dose and check for side…

This study tests whether giving a higher, targeted dose of radiation to the most aggressive parts of a glioblastoma brain tumor can help people live longer. The radiation plan is adjusted during treatment based on MRI scans. The trial includes 30 adults with newly diagnosed gliob…

This study tests a precise type of radiation therapy for people with newly diagnosed brain tumors (grade II-IV glioma). The goal is to see if this technique can effectively treat the tumor while reducing damage to the scalp and lowering the risk of infection or other wound proble…

This early-phase study tests whether a new type of immune cell therapy, made from the patient's own cells and modified to target a protein called CD70, is safe and feasible for adults with glioblastoma and children with high-grade gliomas. The therapy includes an extra modificati…

This study tests whether adding the drug veliparib to standard radiation and chemotherapy can help children and young adults with a newly diagnosed aggressive brain tumor called high-grade glioma. Veliparib blocks a protein that helps cancer cells repair themselves, potentially m…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 52 adults will receive the combination to see if it improves survival and controls the …

This study tests whether the immunotherapy drug nivolumab can help control brain tumors called gliomas that have specific genetic changes (IDH mutations). About 62 adults with these tumors will receive nivolumab through an IV every few weeks. The main goal is to see if the drug c…

This study tests whether a ketogenic diet (high fat, low carbs) combined with the diabetes drug metformin is safe and tolerable for people with glioblastoma, an aggressive brain cancer. The goal is to lower blood sugar, which may slow tumor growth. Participants work with a nutrit…

This early-stage study tests whether adding the experimental drug OKN-007 to standard chemotherapy and radiation is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 adults will receive the combination after surgery. The goal i…

This study tests a targeted therapy called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The goal is to see if the drug can reach the tumor and slow down its growth. About 45 adults with recurrent glioblastoma will take the drug before surgery a…

This early-phase study tests whether adding the experimental drug ruxolitinib to standard brain cancer treatment (radiation and temozolomide) is safe and tolerable for people with newly diagnosed high-grade gliomas or glioblastoma. About 60 participants will receive the combinati…

This study tests an experimental drug called vebreltinib (PLB1001) in people with a specific type of recurrent brain cancer (secondary glioblastoma with IDH mutation and ZM fusion gene). About 84 participants will receive either vebreltinib or standard chemotherapy. The main goal…

This study tests whether starting chemotherapy earlier and continuing it longer can help adults with glioblastoma, an aggressive brain tumor, live longer. About 486 participants are randomly assigned to either the standard treatment or an intensified plan. The goal is to see if t…

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, an aggressive brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. Ab…

This early-stage study tests two immunotherapy drugs (domvanalimab and zimberelimab) in people whose glioblastoma has come back after initial treatment. The goal is to check safety and see how the drugs affect the tumor and immune system. About 46 participants will receive the dr…

This early-phase trial tests whether specially engineered immune cells (IL13Rα2-CAR T cells) can safely target and destroy brain tumor cells that have spread to the lining of the brain and spinal cord. Ten adults with glioblastoma, ependymoma, or medulloblastoma will receive thes…

This study tests whether adding veliparib to standard chemotherapy (temozolomide) helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The cancer must have a specific genetic marker (MGMT hypermethylation). About 447 participants will receive either t…

This early-phase study tests a genetically engineered virus (rQNestin34.5v.2) that targets and kills brain tumor cells. About 62 adults with recurrent malignant glioma will receive the virus injected directly into the tumor, sometimes with a drug called cyclophosphamide to boost …

This study tests a drug called indoximod, which aims to help the immune system fight brain tumors. It is for children aged 3 to 21 with certain types of progressive brain cancer or a newly diagnosed brainstem tumor (DIPG). Participants receive indoximod alongside standard chemoth…

This study tests whether giving a higher, more focused dose of radiation (using advanced photon or proton beams) along with the chemotherapy drug temozolomide helps people with newly diagnosed glioblastoma live longer compared to standard radiation. About 600 participants are enr…

This study tests whether adding anlotinib hydrochloride to the standard Stupp regimen can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with confirmed glioblastoma will receive either the standard treatment plu…

This study tests whether adding an experimental drug called BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults will receive the combination, and researchers will track ho…

This study tests whether a shorter, higher-dose radiation treatment works as well as the standard longer course for people with glioblastoma, an aggressive brain cancer. About 170 adults with confirmed glioblastoma will receive either short or standard radiation. The goal is to s…

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This study tests a new treatment called IGV-001 for people recently diagnosed with glioblastoma, an aggressive brain cancer. The treatment uses a patient's own cells to create a personalized immunotherapy aimed at slowing tumor growth. About 93 participants will receive either IG…

This study tests a new drug, azeliragon, combined with radiation therapy for people with a specific type of glioblastoma, an aggressive brain cancer. The goal is to see if this combination is safe and can slow cancer growth. About 30 adults with newly diagnosed, unmethylated glio…

This study tests an online mind-body program for people with brain tumors (glioma or cancer spread to the brain) and their partners. The program aims to improve spiritual well-being, sleep, mood, and overall quality of life. About 74 couples will participate to see if the program…

This early-phase trial studies how two oral drugs, defactinib and VS-6766, reach glioblastoma tumors in the brain. Fourteen patients with new or recurrent glioblastoma will receive a single dose before surgery, and drug levels will be measured in tumor tissue and blood. The goal …

This study explores whether an Apple Watch can detect changes in walking, heart rate, breathing, and sleep in people with glioblastoma. Researchers aim to use this data to predict complications like seizures or blood clots before they happen. The study involves 25 adults with new…

This study is observing 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how they respond to chemotherapy and targeted therapy. Researchers are tracking survival and tumor progression over time. The goal is to gather real-world data to guide future tr…

This study looks at how doctors share information about brain tumors, scan results, and treatment choices with patients and their caregivers. Researchers hope to learn what helps or hinders clear communication about prognosis and care goals. About 309 people with glioblastoma, th…

This study tests a new ultrasound system (SonoClear®) to see if it gives clearer images during brain tumor surgery compared to standard methods. About 15 adults with glioma (a type of brain tumor) will take part. The goal is to reduce image noise and help surgeons see better, whi…

This study aims to learn how T cells (a type of immune cell) change in the blood and bone marrow of people with glioblastoma, a serious brain cancer. Researchers will collect samples from 40 patients before and during treatment to find patterns that could lead to new immune-based…

This study looks at whether advanced MRI scans can better predict how patients with newly diagnosed glioblastoma respond to Optune therapy compared to standard MRI. About 60 participants will be followed to see how many are alive at six months and one year. The goal is to improve…